参考文献 References
[1] HOSSEINI E S, KASHANI N R, NIKZAD H, et al. The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies [J]. 2020.
[2] YAO H, SONG Y, CHEN Y, et al. Molecular architecture of the SARS-CoV-2 virus [J]. Cell, 2020.
[3] WU F, ZHAO S, YU B, et al. A new coronavirus associated with human respiratory disease in China [J]. Nature, 2020, 579(7798): 1-8.
[4] ROUJIAN, ZHAO, XIANG, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding [J].
[5] NAQVI A, FATIMA K, MOHAMMAD T, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach [J]. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2020: 165878.
[6] KADAM S B, SUKHRAMANI G S, BISHNOI P, et al. SARS‐CoV‐2, the pandemic coronavirus: Molecular and structural insights [J]. Journal of Basic Microbiology, 2021.
[7] HEILINGLOH C S, AUFDERHORST U W, SCHIPPER L, et al. Susceptibility of SARS-CoV-2 to UV Irradiation [J]. American Journal of Infection Control, 2020.
[8] KRATZEL A, TODT D, V'KOVSKI P, et al. Efficient inactivation of SARS-CoV-2 by WHO-recommended hand rub formulations and alcohols [J]. 2020.
[9] GV A, VG B, CG C, et al. Considerations on water quality and the use of chlorine in times of SARS-CoV-2 (COVID-19) pandemic in the community [J]. Case Studies in Chemical and Environmental Engineering, 2020, 2.
[10] COMMISSION N H. 新型冠状病毒肺炎诊疗方案（试行第八版） [J]. 中国病毒病杂志, 2020, 10(5): 8.
[11] ABOUBAKR H A, SHARAFELDIN T A, GOYAL S M. Stability of SARS-CoV-2 and other coronaviruses in the environment and on common touch surfaces and the influence of climatic conditions: a review [J]. Transboundary and Emerging Diseases, 2020.
[12] WU A, WANG L, ZHOU H Y, et al. One year of SARS-CoV-2 evolution [J]. Cell host & microbe, 2021, 29(4).
[13] SINGH J, PANDIT P, MCARTHUR A G, et al. Evolutionary trajectory of SARS-CoV-2 and emerging variants [J]. (1743-422X (Electronic)).
[14] KOYAMA T, PLATT D, PARIDA L. Variant analysis of SARS-CoV-2 genomes [J]. (1564-0604 (Electronic)).
[15] BOEHM E, KRONIG I, NEHER R A, et al. Novel SARS-CoV-2 variants: the pandemics within the pandemic [J]. (1469-0691 (Electronic)).
[16] The biological and clinical significance of emerging SARS-CoV-2 variants [J]. Nature Reviews Genetics.
[17] ZHANG L, JACKSON C B, MOU H, et al. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. LID - 2020.06.12. 148726 [pii] LID -
10.1101/2020.06.12.148726 [doi] [J].
[18] CHEN J, WANG R, WANG M, et al. Mutations Strengthened SARS-CoV-2 Infectivity [J]. (1089-8638 (Electronic)).
[19] LUNDSTROM K, SEYRAN M, PIZZOL D A-O, et al. Viewpoint: Origin of SARS-CoV-2. LID - 10.3390/ v12111203 [doi] LID - 1203 [J]. (1999-4915 (Electronic)).
[20] HUANG Y, XIE J, GUO Y, et al. SARS-CoV-2: Origin, Intermediate Host and Allergenicity Features and Hypotheses [J]. Healthcare, 2021, 9(9): 1132.
[21] HU B, GUO H, ZHOU P, et al. Characteristics of SARS-CoV-2 and COVID-19 [J]. Nature Reviews Microbiology.
[22] MEYEROWITZ E A, RICHTERMAN A, GANDHI R T, et al. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors [J]. Annals of Internal Medicine, 2020, 174(1).
[23] WANG P. Mechanisms of SARS-CoV-2 transmission and pathogenesis [J]. Trends in Immunology, 2020.
[24] WOROBEY M, PEKAR J, LARSEN B B, et al. The emergence of SARS-CoV-2 in Europe and North America [J]. Science, 2020, 370(6516).
[25] CANDIDO D A-O, CLARO I A-O, DE JESUS J A-O X, et al. Evolution and epidemic spread of SARS-CoV-2 in Brazil [J]. (1095-9203 (Electronic)).
[26] POPOVA A Y, SMIRNOV V A-O, ANDREEVA E E, et al. SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic. LID - 10.3390/v13081648 [doi] LID - 1648 [J]. (1999-4915 (Electronic)).
[27] SALIAN V S, WRIGHT J A, VEDELL P T, et al. COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies [J]. Molecular Pharmaceutics, 2021.
[28] LI J, HUANG D Q, ZOU B, et al. Epidemiology of COVID: A Systematic Review and Meta゛nalysis of Clinical Characteristics, Risk factors and Outcomes [J]. Journal of Medical Virology, 2020.
[29] BERLIN D A, GULICK R M, MARTINEZ F J. Severe Covid-19 [J]. The New England journal of medicine, 2020, 383(25): 2451-60.
[30] LAFAIE L, CéLARIER T, GOETHALS L, et al. Recurrence or Relapse of COVID-19 in Older Patients: A Description of Three Cases [J]. Journal of the American Geriatrics Society, 2020.
[31] BEYERSTEDT S, CASARO E B, RANGEL R B. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection [J]. European Journal of Clinical Microbiology & Infectious Diseases, 2021, (4): 1-15.
[32] High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa [J]. 国际口腔科学杂志（英文版）, 2020, (00): E051-E.
[33] SUNGNAK W, HUANG N, BéCAVIN C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes [J]. Nature medicine, 2020: 1-7.
[34] HOU Y J, OKUDA K, EDWARDS C E, et al. SARS- CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract [J]. Cell, 2020, 182(2).
[35] HOFFMANN M, KLEINE-WEBER H, PHLMANN S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells [J]. Molecular Cell, 2020, 78(4).
[36] ZHAO M M, YANG W L, YANG F Y, et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development [J]. Signal Transduction and Targeted Therapy, 2021, 6(1).
[37] PEACOCK T P, GOLDHILL D H, ZHOU J, et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets [J]. Nature Microbiology, 2021: 1-11.
[38] HOFFMANN M, KLEINE-WEBER H, SCHROEDER S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor [J]. Cell, 2020, 181(2).
[39] SUNGNAK W, HUANG N, BéCAVIN C, et al. SARS-CoV-2 Entry Genes Are Most Highly Expressed in Nasal Goblet and Ciliated Cells within Human Airways [J]. 2020.
[40] V'KOVSKI P, KRATZEL A, STEINER S, et al. Coronavirus biology and replication: implications for SARS-CoV-2 [J]. Nature Reviews Microbiology, 2020.
[41] HILLEN H S, KOKIC G, FARNUNG L, et al. Structure of replicating SARS-CoV-2 polymerase [J]. Nature, 2020, 584(7819): 1-6.
[42] YAJING, YUANXIONG, CHENG, et al. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools [J]. 中国病毒学:英文版, 2020, (3): 266-71.
[43] LI Q, GUAN X, WU P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus- Infected Pneumonia [J]. (1533-4406 (Electronic)).
[44] EASTIN C, EASTIN T. Clinical Characteristics of Coronavirus Disease 2019 in China [J]. Journal of Emergency Medicine, 2020, 58(4): 711-2.
[45] LAUER S A, GRANTZ K H, BI Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application [J]. Annals of internal medicine, 2020, 172(9).
[46] GIACOMELLI A, PEZZATI L, CONTI F, et al. Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study [J]. (1537-6591 (Electronic)).
[47] WU Z, MCGOOGAN J M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention [J]. (1538-3598 (Electronic)).
[48] SHI H, HAN X, JIANG N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study [J]. The Lancet Infectious Diseases, 2020, 20(4).
[49] EASTIN C, EASTIN T. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China [J]. Journal of Emergency Medicine, 2020, 58(4): 713-4.
[50] SONG P, LI W, XIE J, et al. Cytokine storm induced by SARS-CoV-2 [J]. Clinica Chimica Acta, 2020, 509.
[51] RASTOGI A. COVID-19 prognosis from a longitudinal dataset [J]. Nature Computational Science.
[52] FANG X, LI S, YU H, et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis [J]. Aging (Albany NY), 12(13).
[53] LAZARUS J V, RATZAN S C, PALAYEW A, et al. A global survey of potential acceptance of a COVID-19 vaccine [J]. Nature medicine, 2020: 1-4.
[54] LE T T, ANDREADAKIS Z, KUMAR A, et al. The COVID-19 vaccine development landscape [J]. Nature Reviews Drug Discovery, 2020.
[55] SANDERS B, KOLDIJK M, SCHUITEMAKER H. Inactivated Viral Vaccines [J]. Springer Berlin Heidelberg, 2015.
[56] IVERSEN P L, BAVARI S. Inactivated COVID-19 vaccines to make a global impact [J]. Lancet Infect Dis, 2021, 21(6): 746-8.
[57] SAEED B Q, AL-SHAHRABI R, ALHAJ S S, et al. Side effects and perceptions following Sinopharm COVID-19 vaccination [J]. (1878-3511 (Electronic)).
[58] XIA S, DUAN K, ZHANG Y, et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials [J]. JAMA The Journal of the American Medical Association, 2020, 324(10).
[59] TOTH K, WOLD W. Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy [J]. Current Gene Therapy, 2013, 13(6): -.
[60] ZHANG C, ZHOU D. Adenoviral vector-based strategies against infectious disease and cancer [J]. Human Vaccines.
[61] FCZ A, XHG B, YHL C, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial [J]. 2020.
[62] ZHU F C, LI Y H, GUAN X H, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial [J]. The Lancet, 2020, 395(10240).
[63] STEPHENSON K E, GARS M L, SADOFF J, et al. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19 [J]. JAMA The Journal of the American Medical Association, 2021, 325(9).
[64] JPA B, WHCA B, USA B. Recombinant protein vaccines, a proven approach against coronavirus pandemics [J]. Advanced Drug Delivery Reviews, 2021.
[65] GILBERT S C, LAMBE T. Recombinant protein vaccines against SARS-CoV-2 [J]. The Lancet Infectious Diseases, 2021.
[66] SY A, YAN L, PLD B, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials - ScienceDirect [J]. 2021.
[67] KEECH C, ALBERT G, CHO I, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine [J]. New England Journal of Medicine, 2020, 383(24).
[68] PUSHPARAJAH D, JIMENEZ S, WONG S, et al. Advances in gene-based vaccine platforms to address the COVID-19 pandemic [J]. Advanced Drug Delivery Reviews, 2021, 170(1).
[69] MMS A, GMSGM B, MM C. DNA vaccines against COVID-19: Perspectives and challenges - ScienceDirect [J]. Life sciences, 2020.
[70] PARK J W, LAGNITON P N P, LIU Y, et al. mRNA vaccines for COVID-19: what, why and how [J]. International Journal of Biological Sciences, 2021, 17(6): 1446-60.
[71] BADEN L R, SAHLY H, ESSINK B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J]. The New England journal of medicine, 384(5): 403-16.
[72] MAHASE E. Covid-19: Moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy [J]. BMJ, 2020, 371.
[73] VERGNES J N. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine [J]. New England Journal of Medicine, 2021, 384(16).
[74] WALSH E E. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates [J]. 四川生理科学杂志, 43(1): 1.
[75] YONG B S, YOU S, JI I R, et al. Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates [J]. Vaccines, 9(4): 307.
[76] TALEGHANI N, TAGHIPOUR F. Diagnosis of COVID-19 for controlling the pandemic: A review of the state-of-the-art - ScienceDirect [J]. Biosensors and Bioelectronics, 2020.
[77] BUSTIN S, MUELLER R, SHIPLEY G, et al. Covid-19 and diagnostic testing for SARS-CoV-2 by RT-qPCR— facts and fallacies [J]. International journal of molecular sciences, 2021, 22(5): 2459.
[78] BORDI L, NICASTRI E, SCORZOLINI L, et al. Differential diagnosis of illness in patients under investigation for the novel coronavirus (SARS-CoV-2), Italy, February 2020 [J]. Eurosurveillance, 2020, 25(8).
[79] CHAN J F, YIP C C, TO K A-O, et al. Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens. LID - 10.1128/JCM.00310-20 [doi] LID - e00310-20 [J]. (1098-660X (Electronic)).
[80] CORMAN V M, LANDT O, KAISER M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR [J]. Eurosurveillance, 2020, 25(3).
[81] KONRAD R, EBERLE U, DANGEL A, et al. Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020 [J]. Eurosurveillance, 2020, 25(9).
[82] Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19 : interim guidelines for collecting, handling, and testing clinical specimens from persons for coronavirus disease 2019 (COVID-19) [J].
[83] TANG Y W, SCHMITZ J E, PERSING D H, et al. The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges [J]. Journal of clinical microbiology, 2020, 58(6).
[84] SULE W F, OLUWAYELU D O. Real-time RT-PCR for COVID-19 diagnosis: challenges and prospects [J]. The Pan African medical journal, 35(Suppl 2): 121.
[85] NR A, DLC B, EN B, et al. Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape - ScienceDirect [J]. Biosensors and Bioelectronics, 2020.
[86] MCDA A, CC A, HP A, et al. SARS-CoV-2 IGM and IGG rapid serologic test for the diagnosis of COVID-19 in the emergency department [J]. Journal of Infection, 2020, 81(5): 816-46.
[87] DELLIèRE S, SALMONA M, MINIER M, et al. Evaluation of the COVID-19 IgG/IgM Rapid Test from Orient Gene Biotech [J]. Journal of clinical microbiology, 58(8): e01233-20.
[88] DRSCHUG A, SCHWANBECK J, HAHN A, et al. Evaluation of the Xiamen AmonMed Biotechnology rapid diagnostic test COVID-19 IgM/IgG test kit (Colloidal gold) [J]. European Journal of Microbiology and Immunology, 2020, 10(3).
[89] HUANG C, WANG Y, LI X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J]. The Lancet, 2020, 395(10223).
[90] CHEN N, ZHOU M, DONG X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J]. The Lancet, 2020, 395(10223).
[91] AI T, YANG Z, HOU H, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases [J]. Radiology, 2020: 200642.
[92] HUSSAIN A, VIA G, MELNIKER L, et al. Multi-organ point-of-care ultrasound for COVID-19 (PoCUS4COVID): international expert consensus [J]. Critical care (London, England), 2020, 24(1): 702.
[93] ZHAO W, ZHONG Z, XIE X, et al. Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study [J]. American Journal of Roentgenology, 2020, 214(5): 1-6.
[94] PENG Q Y, WANG X T, ZHANG L N. Findings of lung ultrasonography of novel corona virus pneumonia during the 2019–2020 epidemic [J]. Intensive Care Medicine, 2020, 46(5): 849-50.
[95] BHANDARI R, KHANNA G, KUHAD A. Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic [J]. European Journal of Pharmacology, 2020, 890.
[96] WANG X, CAO R, ZHANG H, et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro [J]. Cell Discovery.
[97] ZHEN Z, ZL C, TX D, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19 [J]. Journal of Infection, 2020, 81(1).
[98] LI Y, XIE Z, LIN W, et al. Efficacy and safety of lopinavir / ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial [J]. 2020.
[99] LIAN N, XIE H, LIN S, et al. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study [J]. Clinical Microbiology and Infection, 2020, 26(7).
[100] ZHOU Y, VEDANTHAM P, LU K, et al. Protease inhibitors targeting coronavirus and filovirus entry [J]. Antiviral Res, 2015, 116: 76-84.
[101] BOUROUIBA L. Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19 [J]. 2020.
[102] WANG M, CAO R, ZHANG L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [J]. Cell Research, 2020, 30(3): 1-3.
[103] WILLIAMSON B N, FELDMANN F, SCHWARZ B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 [J]. Nature, 2020.
[104] CAI Q, YANG M, LIU D, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study [J]. Engineering, 2020.
[105] GROUP. F O S. Preliminary report of the Favipiravir Observational Study in Japan. [J]. The Japanese Association for Infectious Diseases, 2020.
[106] CHEN F, CHAN K H, JIANG Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds [J]. Journal of Clinical Virology, 2004, 31(1): 69-75.
[107] HORBY P W, MAFHAM M, BELL J L, et al. Lopinavir– ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial [J]. The Lancet, 2020, 396(10259): 1345-52.
[108] ROBACK J D, GUARNER J. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges [J]. JAMA The Journal of the American Medical Association, 2020, 323(16).
[109] JOYNER M, WRIGHT R S, FAIRWEATHER D L, et al. Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients [J]. 2020.
[110] JOYNER M J, SENEFELD J W, KLASSEN S A, et al. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three- Month Experience [J]. 2020.
[111] JAHANSHAHLU L, REZAEI N. Monoclonal antibody as a potential anti-COVID-19 [J]. Biomedicine & Pharmacotherapy, 2020: 110337.
[112] CHEN P, NIRULA A, HELLER B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19 [J]. New England Journal of Medicine, 2020, 384(3).
[113] GROUP S. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 [J]. New England Journal of Medicine, 2020, 384(10).
[114] WEINREICH D M, SIVAPALASINGAM S, NORTON T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 [J]. The New England journal of medicine, 384(3): 238-51.
[115] BAUM A. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters [J]. 四川生理科学杂志, 43(1): 1.
[116] CHAUDHRY D, SINGH P K. Tocilizumab and COVID-19 [J]. Indian Journal of Critical Care Medicine, 2020, 24(9): 741-3.
[117] PT A, SPB C, MCD E, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy - ScienceDirect [J]. Autoimmunity Reviews, 2020, 19(7).
[118] PAN H, PETO R, HENAO-RESTREPO A M, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results [J]. New England Journal of Medicine, 2021.
[119] SHALHOUB S. Interferon beta-1b for COVID-19 [J]. The Lancet, 2020, 395(10238).
[120] Stem cell therapy for COVID‐19, ARDS and pulmonary fibrosis [J]. Cell Proliferation, 2020.
[121] SS A, SS B, AS C, et al. Mesenchymal stem cell therapies for COVID-19: Current status and mechanism of action [J]. Life sciences, 262.
[122] JAYARAMAYYA K, MAHALAXMI I, SUBRAMANIAM M D, et al. Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment [J]. BMB reports, 2020, 53(8).
[123] 间充质干细胞治疗新型冠状病毒肺炎专家共识（2021年，北京） [J]. 传染病信息, 2021, 34(02): 99-106 %@ 1007-8134 %L 11-3886/R %W CNKI.
[124] DING Y, ZENG L, LI R, et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function [J]. BMC Complement Altern Med, 2017, 17(1): 130.
[125] RUNFENG L, YUNLONG H, JICHENG H, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) [J]. Pharmacol Res, 2020, 156: 104761.
[126] CHEN X, WU Y, CHEN C, et al. Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening [J]. Acta Pharm Sin B, 2021, 11(1): 222-36.
[127] XU J, ZHANG Y. Traditional Chinese Medicine treatment of COVID-19 [J]. Complementary Therapies in Clinical Practice, 2020: 101165.
[128] GU M, LIU J, SHI N N, et al. Analysis of property and efficacy of traditional Chinese medicine in staging revention and treatment of coronavirus disease 2019 [J]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2020, 45(6): 1253-8.
[129] LI Y, LI J, ZHONG D, et al. Clinical practice guidelines and experts' consensuses of traditional Chinese herbal medicine for novel coronavirus (COVID-19): protocol of a systematic review [J]. Systematic Reviews, 2020, 9(1).